The massive 2005-2021 growth in private equity was fueled by North American pension plans increasing their allocations. That market is now mature. The next wave of industry growth will come from entirely different sources: insurance companies, international LPs (especially Middle East/Asia), and the vast wealth and retail market.

Public pensions may invest in private assets not only for potential outperformance but to avoid the daily mark-to-market volatility of public markets. This 'volatility washing' creates an illusion of stability that may not reflect the true economic risks of the underlying assets, serving as a poor reason to invest.

A key mindset difference exists between Asian and Western healthcare investors. Asian VCs are often generalists who prefer de-risked, later-stage assets and even invest in infrastructure like hospitals. This indicates a more risk-averse thesis compared to specialized Western VCs focused on early-stage biotech.

A key cultural difference in venture capital is that European VCs often request late-stage metrics like five-year financial projections from pre-seed companies. This contrasts sharply with the US/SF focus on market size, team, and vision at the earliest stages of a company's life.

A novel model uses philanthropic capital to fund an "aligned intermediary" that sources no-fee climate deals for pension funds. This is more effective than funding research, as it directly solves the pensions' access problem and deploys capital.

Due to their monopolistic and conservative nature, pension funds punish deviation from the peer group. Innovating is a career risk, as it requires justification for being different. Consequently, significant change rarely happens proactively; instead, it is forced upon these institutions by external market crises.

Unlike their US counterparts, European biotechs have less access to large venture funds. This forces a culture of extreme capital efficiency and discipline. This need to be "cleverer, smarter with less people and less money" is a defining feature and potential advantage of the European ecosystem.

Botha argues venture capital isn't a scalable asset class. Despite massive capital inflows (~$250B/year), the number of significant ($1B+) exits hasn't increased from ~20 per year. The math for industry-wide returns doesn't work, making it a "return-free risk" for many LPs.

While limited partners in venture funds often claim to seek differentiated strategies, in reality, they prefer minor deviations from established models. They want the comfort of the familiar with a slight "alpha" twist, making it difficult for managers with genuinely unconventional approaches to raise institutional capital.